<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BREVIBLOC- esmolol hydrochloride injection </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BREVIBLOC safely and effectively.  See full prescribing information for BREVIBLOC injection.<br>BREVIBLOC (Esmolol Hydrochloride) injection, for intravenous use Initial U.S. Approval: 1986</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: </p>
<dl>
<dt>•</dt>
<dd>Control of ventricular rate in <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and control of heart rate in noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>  (<a href="#i4i_section_id_e9b62b91-a227-43f1-8966-4ceabcf71389">1.1</a>)</dd>
<dt>•</dt>
<dd>Control of perioperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>  (<a href="#i4i_section_id_6ad3564a-2de5-408b-b563-8380fd412a08">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Administer intravenously  (<a href="#i4i_section_id_13a8a48a-8cea-4ec2-b58f-c00c729d33e3">2.1</a>, <a href="#i4i_section_id_d2e3eeb8-e125-46c4-97b1-a838a554f797">2.2</a>)</dd>
<dt>•</dt>
<dd>Titrate using ventricular rate or blood pressure at ≥4-minute intervals.  (<a href="#i4i_section_id_13a8a48a-8cea-4ec2-b58f-c00c729d33e3">2.1</a>, <a href="#i4i_section_id_d2e3eeb8-e125-46c4-97b1-a838a554f797">2.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular tachycardia</span> (SVT) or noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>  (<a href="#i4i_section_id_13a8a48a-8cea-4ec2-b58f-c00c729d33e3">2.1</a>)<dl>
<dt>1.</dt>
<dd>Optional loading dose: 500 mcg per kg infused over one minute</dd>
<dt>2.</dt>
<dd>Then 50 mcg per kg per minute for the next 4 minutes</dd>
<dt>3.</dt>
<dd>Adjust dose as needed to a maximum of 200 mcg per kg per minute.  </dd>
<dt>4.</dt>
<dd>Additional loading doses may be administered  </dd>
</dl>
</dd>
<dt>•</dt>
<dd>Perioperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>  (<a href="#i4i_section_id_d2e3eeb8-e125-46c4-97b1-a838a554f797">2.2</a>)<dl>
<dt>5.</dt>
<dd>Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control)</dd>
<dt>6.</dt>
<dd>Then 50 mcg per kg per min for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) or 300 (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) mcg per kg per min  (<a href="#i4i_section_id_d2e3eeb8-e125-46c4-97b1-a838a554f797">2.2</a>)</dd>
</dl>
</dd>
</dl></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Injection: 100 mg/10 mL (10 mg/mL) in 10 mL vial  (<a href="#i4i_dosage_form_strength_id_eebf84e5-c2c8-48c6-8ec8-5f9879a24c9f">3</a>)</dd>
<dt>•</dt>
<dd>Injection: 2500 mg/250 mL (10 mg/mL) in 250 mL Premixed Injection bag  (<a href="#i4i_dosage_form_strength_id_eebf84e5-c2c8-48c6-8ec8-5f9879a24c9f">3</a>)</dd>
<dt>•</dt>
<dd>Injection: 2000 mg/100 mL (20 mg/mL) in 100 mL Double Strength Premixed Injection bag  (<a href="#i4i_dosage_form_strength_id_eebf84e5-c2c8-48c6-8ec8-5f9879a24c9f">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart block</span> greater than first degree  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span>  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Decompensated heart failure</span>  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span>  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
<dt>•</dt>
<dd>Coadministration of IV cardiodepressant calcium-channel antagonists (e.g.  verapamil) in close proximity to BREVIBLOC injection (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>, <a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span>  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to esmolol  (<a href="#i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>: Monitor for signs and symptoms of cardiovascular adverse effects.  Reduce or discontinue use  (<a href="#i4i_section_id_fd648111-dc5e-4ba0-8c7b-ee82bc51e45c">5.1</a>, <a href="#i4i_section_id_358d1817-285e-4f01-8f58-a41be28dacf5">5.2</a>, <a href="#i4i_section_id_cff29eba-0683-4156-8796-f0a1fb4a0159">5.3</a>, <a href="#i4i_section_id_c4847894-e4f9-49e3-8675-e87184d74437">5.10</a>)</dd>
<dt>•</dt>
<dd>Risk of exacerbating reactive airway disease  (<a href="#i4i_section_id_e288719a-752a-4dfa-82ab-726ad80aacbd">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus: Increases the effect of hypoglycemic agents and masks hypoglycemic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>  (<a href="#i4i_section_id_9c398d65-da00-45e5-82e4-b27dd18029f4">5.6</a>)</dd>
<dt>•</dt>
<dd>Risk of unopposed alpha-agonism and severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in untreated <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>  (<a href="#i4i_section_id_682c0145-c0b1-4cd6-89d6-ba893c7cf2e1">5.9</a>)</dd>
<dt>•</dt>
<dd>Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> when abruptly discontinued in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>  (<a href="#i4i_section_id_52c26583-a4a5-43ba-9c18-be97c92bb5ff">5.12</a>, <a href="#i4i_section_id_b4bca6ed-4bb6-40cf-a7b7-70ae45befef1">5.15</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt;10%) are symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) and asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<a href="#i4i_adverse_effects_id_7bd3d14f-d302-4e5e-a188-2f46bf98ee18">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or<span class="Italics"><a href="http://www.fda.gov/medwatch"> www.fda.gov/medwatch</a></span>.</span> </p>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Digitalis glycosides: Risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>  (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
<dt>•</dt>
<dd>Anticholinesterases: Prolongs <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>  (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
<dt>•</dt>
<dd>Antihypertensive agents: Risk of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span>  (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
<dt>•</dt>
<dd>Sympathomimetic drugs: Dose adjustment needed  (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
<dt>•</dt>
<dd>Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use  (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)</dd>
</dl></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span> or Noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus Tachycardia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing for the Treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span> or Noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus Tachycardia</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Transition from BREVIBLOC Injection Therapy to Alternative Drugs</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Directions for Use</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Reactive Airways Disease</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Infusion Site Reactions</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Use in Patients with Prinzmetal's Angina</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Use in Patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Use in Hypovolemic Patients</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Use in Patients with Peripheral Circulatory Disorders</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Abrupt Discontinuation of BREVIBLOC Injection</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Patients with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Use in Patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Use in Patients at Risk of Severe Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Treatment Recommendations</a></h2>
<h2><a href="#section-9.3" class="toc">10.3 Dilution Errors</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc">11.1 BREVIBLOC Injection Dosage Forms</a></h2>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_70f1a8c7-5f16-4af7-b7be-11bdf6ba9b24"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9b62b91-a227-43f1-8966-4ceabcf71389"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span> or Noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus Tachycardia</span></h2>
<p class="First">BREVIBLOC (Esmolol Hydrochloride) is indicated for the rapid control of ventricular rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable.  BREVIBLOC is also indicated in noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span> where, in the physician’s judgment, the rapid heart rate requires specific intervention.  BREVIBLOC is intended for short-term use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ad3564a-2de5-408b-b563-8380fd412a08"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">BREVIBLOC (Esmolol Hydrochloride) is indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.</p>
<p>Use of BREVIBLOC to prevent such events is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4bdbdefa-5e7c-4317-9750-0d6c6e052e47"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13a8a48a-8cea-4ec2-b58f-c00c729d33e3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing for the Treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span> or Noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus Tachycardia</span></h2>
<p class="First">BREVIBLOC is administered by continuous intravenous infusion with or without a loading dose.  Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response.</p>
<a name="_RefID9A7FF1D96D9945EBA06D1EF798899D4D"></a><table width="100%">
<caption><span>Table 1 Step-Wise Dosing </span></caption>
<col width="8%">
<col width="92%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First">Step</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Action</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Optional loading dose (500 mcg per kg over 1 minute), then 50 mcg per kg per min for 4 min</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Optional loading dose if necessary, then 100 mcg per kg per min for 4 min</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Optional loading dose if necessary, then 150 mcg per kg per min for 4 min</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule"><p class="First">If necessary, increase dose to 200 mcg per kg per min</p></td>
</tr>
</tbody>
</table>
<p>In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes.</p>
<p>The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate.  Dosages greater than 200 mcg per kg per minute provide little added heart rate lowering effect, and the rate of adverse reactions increases.</p>
<p>Maintenance infusions may be continued for up to 48 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2e3eeb8-e125-46c4-97b1-a838a554f797"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">In this setting it is not always advisable to slowly titrate to a therapeutic effect.  Therefore two dosing options are presented: immediate control and gradual control.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88d497af-70ae-4314-bd45-340b19cdccc6"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold">Immediate Control</span></h3>
<dl>
<dt>•</dt>
<dd>Administer 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary.</dd>
<dt>•</dt>
<dd>Adjust the infusion rate as required to maintain desired heart rate and blood pressure.  Refer to Maximum Recommended Doses below.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0f8970d-469d-481d-a11b-eae44634fba0"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold">Gradual Control</span></h3>
<dl>
<dt>•</dt>
<dd>Administer 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes.</dd>
<dt>•</dt>
<dd>Depending on the response obtained, continue dosing as outlined for <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>.  Refer to Maximum Recommended Doses below.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de50675e-e216-46c6-a2da-21f33f2402d6"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold">Maximum Recommended Doses</span></h3>
<dl>
<dt>•</dt>
<dd>For the treatment of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, maintenance infusion dosages greater than 200 mcg per kg per min are not recommended; dosages greater than 200 mcg per kg per min provide little additional heart rate-lowering effect, and the rate of adverse reactions increases.</dd>
<dt>•</dt>
<dd>For the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, higher maintenance infusion dosages (250-300 mcg per kg per min) may be required.  The safety of doses above 300 mcg per kg per minute has not been studied.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57874862-aa99-4a6d-ab90-f1b1edcfafd2"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Transition from BREVIBLOC Injection Therapy to Alternative Drugs</h2>
<p class="First">After patients achieve adequate control of the heart rate and a stable clinical status, transition to alternative antiarrhythmic drugs may be accomplished.</p>
<p>When transitioning from BREVIBLOC to alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of BREVIBLOC as follows:</p>
<dl>
<dt>•</dt>
<dd>Thirty minutes following the first dose of the alternative drug, reduce the BREVIBLOC infusion rate by one-half (50%).</dd>
<dt>•</dt>
<dd>After administration of the second dose of the alternative drug, monitor the patient’s response and if satisfactory control is maintained for the first hour, discontinue the BREVIBLOC infusion.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_783f65fd-89a6-4863-8f38-21343e5fbb6d"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Directions for Use</h2>
<p class="First">BREVIBLOC injection is available in a pre-mixed bag and ready-to-use vial. BREVIBLOC is not compatible with Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> (5%) solution (limited stability) or furosemide (precipitation).</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09d48368-7b03-4e4f-ab88-76817c9491e2"></a><a name="section-2.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Premixed Bag</span></span></h3>
<dl>
<dt>•</dt>
<dd>The medication port is to be used solely for withdrawing an initial bolus from the bag.</dd>
<dt>•</dt>
<dd>Use aseptic technique when withdrawing the bolus dose.</dd>
<dt>•</dt>
<dd>Do not add any additional </dd>
</dl>
<div class="Figure">
<a name="id738"></a><img alt="Figure 1: Two-Port INTRAVIA Bag" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-01.jpg"><p class="MultiMediaCaption">Figure 1: Two-Port INTRAVIA Bag </p>
</div>
<p class="First">Figure 1: Two-Port INTRAVIA Bag </p>
<dl>
<dt>•</dt>
<dd> medications to the bag.</dd>
</dl>
<p>Figure 1: Two-Port INTRAVIA Bag </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95fa6e56-0314-49cd-a6af-c6393d131e0a"></a><a name="section-2.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Ready-to-Use Vial</span></span></h3>
<p class="First">The Ready-to-use Vial may be used to administer a loading dosage by hand-held syringe while the maintenance infusion is being prepared<span class="Italics">[see How Supplied/Storage and Handling (<a href="#i4i_section_id_91e02119-d1d3-4737-880e-194cd33e5ae6">16.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7498bd6-20c4-4bff-99b4-fb5065f70d2d"></a><a name="section-2.4.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Compatibility with Commonly Used Intravenous Fluids</span></span></h3>
<p class="First">BREVIBLOC was tested for compatibility with ten commonly used intravenous fluids at a final concentration of 10 mg esmolol hydrochloride per mL.  BREVIBLOC was found to be compatible with the following solutions and was stable for at least 24 hours at controlled room temperature or under refrigeration:</p>
<dl>
<dt>•</dt>
<dd>Dextrose (5%) Injection, USP</dd>
<dt>•</dt>
<dd>Dextrose (5%) in Lactated Ringer’s Injection</dd>
<dt>•</dt>
<dd>Dextrose (5%) in Ringer’s Injection</dd>
<dt>•</dt>
<dd>Dextrose (5%) and Sodium Chloride (0.45%) Injection, USP</dd>
<dt>•</dt>
<dd>Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP</dd>
<dt>•</dt>
<dd>Lactated Ringer’s Injection, USP</dd>
<dt>•</dt>
<dd>Potassium Chloride (40 mEq/liter) in Dextrose (5%) Injection, USP</dd>
<dt>•</dt>
<dd>Sodium Chloride (0.45%) Injection, USP</dd>
<dt>•</dt>
<dd>Sodium Chloride (0.9%) Injection, USP</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_eebf84e5-c2c8-48c6-8ec8-5f9879a24c9f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">All BREVIBLOC dosage forms are iso-osmotic solutions of esmolol hydrochloride in sodium chloride.</p>
<a name="_RefID949C491AC86C4ACDAAD76F9213A3E424"></a><table width="100%">
<caption><span>Table 2 BREVIBLOC Injection Presentations </span></caption>
<col width="19%">
<col width="28%">
<col width="27%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Product Name</p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">BREVIBLOC</p>
<p>PREMIXED Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">BREVIBLOC</p>
<p>DOUBLE STRENGTH PREMIXED Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">BREVIBLOC Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Total Dose</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2500 mg / 250 mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2000 mg / 100 mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 mg / 10 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Esmolol Hydrochloride Concentration</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 mg/mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">20 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg/mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Packaging</p></td>
<td class="Botrule Lrule" align="center"><p class="First">250 mL  Bag</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100 mL Bag</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mL Vial</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_74df2e50-8af8-4d9e-ac97-82a568f5d439"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">BREVIBLOC (Esmolol Hydrochloride) is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>:  May precipitate or worsen <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> resulting in <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_358d1817-285e-4f01-8f58-a41be28dacf5">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart block</span> greater than first degree:  Second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> may precipitate or worsen <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> resulting in <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_358d1817-285e-4f01-8f58-a41be28dacf5">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span>:  May precipitate or worsen <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> resulting in <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_358d1817-285e-4f01-8f58-a41be28dacf5">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Decompensated heart failure</span>:  May worsen <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span>:  May precipitate further <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> and cause <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</dd>
<dt>•</dt>
<dd>IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrests</span> have occurred in patients receiving BREVIBLOC and intravenous verapamil.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span>:  May precipitate cardiorespiratory compromise.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_3e752c8c-576e-4191-917c-1abf8ce4b155"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd648111-dc5e-4ba0-8c7b-ee82bc51e45c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> can occur at any dose but is dose-related.  Patients with hemodynamic compromise or on interacting medications are at particular risk.  Severe reactions may include <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  For control of ventricular heart rate, maintenance doses greater than 200 mcg per kg per min are not recommended.  Monitor patients closely, especially if pretreatment blood pressure is low.  In case of an unacceptable <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>, reduce or stop BREVIBLOC injection.  Decrease of dose or termination of infusion reverses <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, usually within 30 minutes. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_358d1817-285e-4f01-8f58-a41be28dacf5"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, including sinus pause, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred with the use of BREVIBLOC injection.  Patients with first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, sinus node dysfunction, or conduction disorders may be at increased risk.  Monitor heart rate and rhythm in patients receiving BREVIBLOC <span class="Italics">[see Contraindications (4)].</span></p>
<p>If severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> develops, reduce or stop BREVIBLOC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cff29eba-0683-4156-8796-f0a1fb4a0159"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Beta blockers, like BREVIBLOC injection, can cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of myocardial contractility and may precipitate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>.  At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, stop BREVIBLOC and start supportive therapy <span class="Italics">[see Overdosage (<a href="#i4i_overdosage_id_f8c9ca62-6c80-4e9d-9a1e-09a3ddd4bfb2">10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab0618c4-5efd-441d-8a96-f0d004feed6f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Monitor vital signs closely and titrate BREVIBLOC slowly in the treatment of patients whose blood pressure is primarily driven by <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> associated with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e288719a-752a-4dfa-82ab-726ad80aacbd"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Reactive Airways Disease</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">reactive airways disease</span> should, in general, not receive beta blockers.  Because of its relative beta<span class="Sub">1</span> selectivity and titratability, titrate BREVIBLOC to the lowest possible effective dose.  In the event of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, stop the infusion immediately; a beta<span class="Sub">2</span> stimulating agent may be administered with appropriate monitoring of ventricular rates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c398d65-da00-45e5-82e4-b27dd18029f4"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, or diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or other hypoglycemic agents, beta blockers may mask <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> occurring with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, but other manifestations such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> may not be masked.</p>
<p>Concomitant use of beta blockers and antidiabetic agents can enhance the effect of antidiabetic agents (blood glucose–lowering).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b865dce-2de9-4569-9c22-5c79167c2420"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Infusion Site Reactions</h2>
<p class="First">Infusion site reactions have occurred with the use of BREVIBLOC injection.  They include irritation, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and severe reactions (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>), in particular when associated with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> <span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_id_7bd3d14f-d302-4e5e-a188-2f46bf98ee18">6</a>)].  </span>Avoid infusions into small veins or through a butterfly catheter.</p>
<p>If a local infusion site reaction develops, use an alternative infusion site and avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf9c37cd-1b4c-44d7-b8ce-8b9d6ecf66bf"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Use in Patients with Prinzmetal's Angina</h2>
<p class="First">Beta blockers may exacerbate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attacks</span> in patients with Prinzmetal’s angina because of unopposed alpha receptor–mediated coronary artery <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>. Do not use nonselective beta blockers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_682c0145-c0b1-4cd6-89d6-ba893c7cf2e1"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Use in Patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">If BREVIBLOC is used in the setting of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated.  Administration of beta-blockers alone in the setting of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> has been associated with a paradoxical increase in blood pressure from the attenuation of beta-mediated vasodilation in skeletal muscle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4847894-e4f9-49e3-8675-e87184d74437"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Use in Hypovolemic Patients</h2>
<p class="First">In hypovolemic patients, BREVIBLOC injection can attenuate <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> and increase the risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b8f8b9b-82db-43ae-a0e9-42367aefb81a"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Use in Patients with Peripheral Circulatory Disorders</h2>
<p class="First">In patients with peripheral circulatory disorders (including Raynaud’s disease or syndrome, and peripheral occlusive vascular disease), BREVIBLOC may aggravate peripheral circulatory disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52c26583-a4a5-43ba-9c18-be97c92bb5ff"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Abrupt Discontinuation of BREVIBLOC Injection</h2>
<p class="First">Severe exacerbations of angina, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> have been reported in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> upon abrupt discontinuation of beta blocker therapy.  Observe patients for signs of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> when discontinuing BREVIBLOC.</p>
<p>Heart rate increases moderately above pretreatment levels 30 minutes after BREVIBLOC discontinuation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee2603d9-ec3b-434c-9d43-5ec69a43ce75"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Beta blockers, including BREVIBLOC, have been associated with increases in serum potassium levels and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. The risk is increased in patients with risk factors such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Intravenous administration of beta blockers has been reported to cause potentially life-threatening <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in hemodialysis patients.  Monitor serum electrolytes during therapy with BREVIBLOC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e342f178-df2e-45b3-82fd-dc58a329cf83"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Use in Patients with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Beta blockers, including BREVIBLOC, have been reported to cause hyperkalemic <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> in general may be associated with reduced cardiac contractility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4bca6ed-4bb6-40cf-a7b7-70ae45befef1"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Use in Patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></h2>
<p class="First">Beta-adrenergic blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Abrupt withdrawal of beta blockade might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>; therefore, monitor patients for signs of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> when withdrawing beta blocking therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ac1e543-60b6-467b-804e-77097c2224e8"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Use in Patients at Risk of Severe Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">When using beta blockers, patients at risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic).</p>
<p>Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> <span class="Italics">[see Drug Interactions (<a href="#i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602">7</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7bd3d14f-d302-4e5e-a188-2f46bf98ee18"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_866d5be4-6b06-44fc-8ad8-abb5f3bb25f0"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The following adverse reaction rates are based on use of BREVIBLOC (Esmolol Hydrochloride) in clinical trials involving 369 patients with <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> and over 600 intraoperative and postoperative patients enrolled in clinical trials.  Most adverse effects observed in controlled clinical trial settings have been mild and transient.  The most important and common adverse effect has been <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see Warnings and Precautions (5.1)].</span>  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported in post-marketing experience occurring during complex clinical states where BREVIBLOC was presumably being used simply to control ventricular rate <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_e288719a-752a-4dfa-82ab-726ad80aacbd">5.5</a>)].</span></p>
<a name="_RefID83934E732CA646EA9DCC2EE07771D61B"></a><table width="100%">
<caption><span>Table 3 Clinical Trial Adverse Reactions (Frequency ≥3%) </span></caption>
<col width="27%">
<col width="37%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">System Organ Class (SOC)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">Preferred MedDRA Term</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Frequency</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3"><p class="First"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span></p></td>
<td class="Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>*</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">25%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><br>(<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</p></td>
<td class="Botrule Lrule"><p class="First">Infusion site reactions<br>(<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Sup">* </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> resolved during BREVIBLOC (Esmolol Hydrochloride) infusion in 63% of patients.  In 80% of the remaining patients, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> resolved within 30 minutes following discontinuation of infusion. </p></td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ee8f68b-8ec9-46a1-b38c-9c6854d9122c"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Clinical Trial Adverse Reactions (Frequency &lt;3%)</span></span></h3>
<p class="First"><span class="Underline">Psychiatric Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (~2%)<br><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> (&lt;1%)</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (~ 2%)<br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, speech disorder, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> (&lt;1%)<br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> (&lt;1%), with one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">Peripheral ischemia</span> (~1%)<br><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (&lt;1%)</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (~1%)<br><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> (&lt;1%)</p>
<p><span class="Underline">Renal and Urinary Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> (&lt;1%)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d5619185-b5e5-4a48-8aa3-1f5934fe614f"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been reported in the post-marketing experience.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, Coronary <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arteriospasm</span></p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_39e83929-f299-44b4-9a1d-2a32e9c2f602"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Concomitant use of BREVIBLOC injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate BREVIBLOC’s effects on blood pressure, contractility, and impulse propagation.  Severe interactions with such drugs can result in, for example, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, sinus pause, <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, and/or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.  In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below.)  BREVIBLOC should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>, including but not limited to:</p>
<dl>
<dt>•</dt>
<dd>Digitalis glycosides:  Concomitant administration of digoxin and BREVIBLOC leads to an approximate 10% to 20% increase of digoxin blood levels at some time points.  Digoxin does not affect BREVIBLOC pharmacokinetics.  Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate.  Concomitant use increases the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</dd>
<dt>•</dt>
<dd>Anticholinesterases:  BREVIBLOC prolonged the duration of succinylcholine-induced <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> and moderately prolonged clinical duration and recovery index of mivacurium.  </dd>
<dt>•</dt>
<dd>Antihypertensive agents clonidine, guanfacine, or moxonidine:  Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span>.  If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.</dd>
<dt>•</dt>
<dd>Calcium channel antagonists:  In patients with depressed myocardial function, use of BREVIBLOC with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrests</span>.</dd>
<dt>•</dt>
<dd>Sympathomimetic drugs:  Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of BREVIBLOC.</dd>
<dt>•</dt>
<dd>Vasoconstrictive and positive inotropic agents:  Because of the risk of reducing cardiac contractility in presence of high systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, do not use BREVIBLOC to control <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_78547f9e-6fc4-44e1-b619-51d4a3df444f"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_69a3b88b-8316-44b0-b3fc-b175284e8da3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C.  Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min).  There are no adequate and well-controlled studies in pregnant women.  BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality.  In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_c61b6e2c-66fa-446d-9d94-e61d071e4a28"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span>, which continued after termination of drug infusion. BREVIBLOC injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_67a224a3-5734-4e18-896e-27e0366e95e7"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BREVIBLOC, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_566e495b-af9f-4888-af20-be4bdd537c23"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of BREVIBLOC in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_86c93bc9-353d-4c68-b5b7-597925770bc5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of BREVIBLOC injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should  usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3cd68970-d38b-4668-b265-c5bfbaac4b4f"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No special precautions are necessary in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because BREVIBLOC is metabolized by red-blood cell esterases <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_clinical_pharmacology_id_69759fef-7117-4050-b641-8b7b03b29d3d">12</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7f387dc-be8f-4635-8260-d0fb302d1d70"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment is required for esmolol in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. There is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours<span class="Italics"> [see Clinical Pharmacology (<a href="#i4i_clinical_pharmacology_id_69759fef-7117-4050-b641-8b7b03b29d3d">12</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f8c9ca62-6c80-4e9d-9a1e-09a3ddd4bfb2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1dc7baaf-b14d-4e14-950a-e0c82c8c508c"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of BREVIBLOC (Esmolol Hydrochloride) can cause cardiac and central nervous system effects.  These effects may precipitate severe signs, symptoms, sequelae, and complications (for example, severe cardiac and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), and may be fatal.  Continuous monitoring of the patient is required.</p>
<dl>
<dt>•</dt>
<dd>Cardiac effects include <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> (1<span class="Sup">st</span> -, 2<span class="Sup">nd</span> -, 3<span class="Sup">rd</span> degree), <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythms</span>, intraventricular conduction delays, decreased cardiac contractility, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (including <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>), <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>/<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, and <span class="product-label-link" type="condition" conceptid="4122762" conceptname="Electromechanical dissociation">pulseless electrical activity</span>.</dd>
<dt>•</dt>
<dd>Central nervous system effects include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, sleep and mood disturbances, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</dd>
<dt>•</dt>
<dd>In addition, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">mesenteric ischemia</span>, peripheral <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and  <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (especially in children) may occur.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d5c382f6-a5e5-4bf7-97b0-23a61ce861d7"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Treatment Recommendations</h2>
<p class="First">Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the BREVIBLOC infusion.  Then, based on the observed clinical effects, consider the following general measures.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></span></p>
<p>Consider intravenous administration of atropine or another anticholinergic drug or cardiac pacing.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span></p>
<p>Consider intravenous administration of a diuretic or digitalis glycoside.  In <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> resulting from inadequate cardiac contractility, consider intravenous administration of dopamine, dobutamine, isoproterenol, or inamrinone.   Glucagon has been reported to be useful.</p>
<p><span class="Underline">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></span></p>
<p>Consider intravenous administration of fluids or vasopressor agents such as dopamine or norepinephrine.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></span></p>
<p>Consider intravenous administration of a beta<span class="Sub">2</span> stimulating agent or a theophylline derivative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af1c33b0-16e1-4f89-91fa-b681f683487a"></a><a name="section-9.3"></a><p></p>
<h2>10.3 Dilution Errors</h2>
<p class="First">Massive accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of BREVIBLOC have resulted from dilution errors.  Use of BREVIBLOC PREMIXED Injection and BREVIBLOC DOUBLE STRENGTH PREMIXED Injection may reduce the potential for dilution errors.  Some of these <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been fatal while others resulted in permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.  Bolus doses in the range of 625 mg to 2.5 g (12.5-50 mg/kg) have been fatal.  Patients have recovered completely from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery.  The patients who survived appear to be those whose circulation could be supported until the effects of BREVIBLOC resolved.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_39a47c87-3cb3-4f12-9274-843bdb12247a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BREVIBLOC (Esmolol Hydrochloride) is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes).  Esmolol hydrochloride is:</p>
<dl>
<dt>•</dt>
<dd>(±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure:</dd>
</dl>
<div class="Figure">
<a name="id1121"></a><img alt="BREVIBLOC Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-02.jpg">
</div>
<dl>
<dt>•</dt>
<dd>Esmolol hydrochloride has the empirical formula C<span class="Sub">16</span>H<span class="Sub">26</span>NO<span class="Sub">4</span>Cl and a molecular weight of 331.8.  It has one asymmetric center and exists as an enantiomeric pair.</dd>
<dt>•</dt>
<dd>Esmolol hydrochloride is a white to off-white crystalline powder.  It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aabd8ee8-4d55-41a6-8d4c-e709a97034c7"></a><a name="section-10.1"></a><p></p>
<h2>11.1 BREVIBLOC Injection Dosage Forms</h2>
<p class="First">All BREVIBLOC presentations are clear, colorless to light yellow, sterile, nonpyrogenic, iso-osmotic solutions of esmolol hydrochloride in sodium chloride.  The formulations for BREVIBLOC PREMIXED Injection, BREVIBLOC DOUBLE STRENGTH PREMIXED Injection, and BREVIBLOC Injection are described in the table below:</p>
<a name="_RefID5BC1DE310EB44D0395BEB33267FDC083"></a><table width="100%">
<caption><span>Table 4 BREVIBLOC Injection Formulations </span></caption>
<col width="19%">
<col width="19%">
<col width="42%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">BREVIBLOC PREMIXED Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">BREVIBLOC<br>DOUBLE STRENGTH PREMIXED Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">BREVIBLOC Injection</p>
<p>(Esmolol Hydrochloride)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Esmolol Hydrochloride, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 mg/mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">20 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Sodium Chloride, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.9 mg/mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.1 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.9 mg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Water for <br>Injection, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Q.S. to volume<br>of 250 mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Q.S. to volume<br>of 100 mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Q.S. to volume<br>of 10 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Sodium Acetate Trihydrate, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.8 mg/mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.8 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8 mg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Glacial Acetic <br>Acid, USP</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.546 mg/mL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.546 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.546 mg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Sodium Hydroxide</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First">Q.S. to adjust pH to 4.5-5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Hydrochloric Acid</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First">Q.S. to adjust pH to 4.5-5.5</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4"><p class="First">Q.S. = Quantity sufficient</p></td></tr>
</tbody>
</table>
<p>The calculated osmolarity of BREVIBLOC PREMIXED Injection and BREVIBLOC DOUBLE STRENGTH PREMIXED Injection is 312 mOsmol/L.  The 250 mL and 100 mL bags are non-latex, non-PVC INTRAVIA bags with dual PVC ports.  The INTRAVIA bags are manufactured from a specially designed multilayer plastic (PL 2408).  Solutions in contact with the plastic container leach out certain chemical compounds from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_69759fef-7117-4050-b641-8b7b03b29d3d"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_313c77ce-9912-493a-9481-7ce80ec48775"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">BREVIBLOC (Esmolol Hydrochloride) is a beta<span class="Sub">1</span>-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages.  Its elimination half-life after intravenous infusion is approximately 9 minutes.  BREVIBLOC inhibits the beta<span class="Sub">1</span> receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta<span class="Sub">2</span> receptors located chiefly in the bronchial and vascular musculature.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_38c169f2-9009-4719-8dcd-35458d94ce30"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of BREVIBLOC, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate.  Blood levels of BREVIBLOC have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10-20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity.</p>
<p>In human electrophysiology studies, BREVIBLOC produced effects typical of a beta blocker: a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade <span class="product-label-link" type="condition" conceptid="318448" conceptname="Second degree atrioventricular block">Wenckebach</span> cycle length.</p>
<p>In patients undergoing radionuclide angiography, BREVIBLOC, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg).  During exercise, BREVIBLOC produced reductions in heart rate, rate pressure product and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> which were also similar to those produced by propranolol, but BREVIBLOC produced a significantly larger <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in systolic blood pressure.  In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of BREVIBLOC produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of BREVIBLOC infusion, all of the hemodynamic parameters had returned to pretreatment levels.</p>
<p>The relative cardioselectivity of BREVIBLOC was demonstrated in 10 mildly <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients. Infusions of BREVIBLOC 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo.  At 300 mcg/kg/min, BREVIBLOC produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and BREVIBLOC was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  No adverse pulmonary effects were observed in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> who received therapeutic dosages of BREVIBLOC for treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (51 patients) or in perioperative settings (32 patients).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca75543c-23b4-4146-a718-f3be41852056"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterases</span> or red cell membrane acetylcholinesterase.  Total body clearance in man was found to be about 20 L/kg/hr, which is greater than <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow.  Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. </p>
<p>Using an appropriate loading dose, steady-state blood levels of BREVIBLOC for dosages from 50-300 mcg/kg/min are obtained within five minutes.  Steady-state is reached in about 30 minutes without the loading dose.  Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range.  Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion.  Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion. </p>
<p>Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine.  Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73-88% of the dosage. </p>
<p>Metabolism of esmolol results in the formation of the corresponding free acid and methanol.  The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade.  The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.  After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis.  The half-life of the acid metabolite of BREVIBLOC, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD.  The peak concentrations of the acid metabolite are doubled in ESRD.</p>
<p>Methanol blood levels, monitored in subjects receiving BREVIBLOC for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity.</p>
<p>BREVIBLOC has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_9d948ec4-e911-48bd-b3ba-3efd4aab1194"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_b041739e-746a-4d2a-868d-2df384745bd6"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span></span></p>
<p>In two multicenter, randomized, double-blind, controlled comparisons of BREVIBLOC injection with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min of BREVIBLOC were found to be more effective than placebo and about as effective as propranolol, 3-6 mg given by bolus injections, in the treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, principally <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>.  The majority of these patients developed their <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> postoperatively.  About 60-70% of the patients treated with BREVIBLOC developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less.  The average effective dosage of BREVIBLOC was approximately 100 mcg/kg/min in the two studies.  Other multicenter baseline-controlled studies gave similar results.  In the comparison with propranolol, about 50% of patients in both the BREVIBLOC and propranolol groups were on concomitant digoxin.  Response rates were slightly higher with both beta blockers in the digoxin-treated patients.</p>
<p>In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was symptomatic (mainly <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was more common with BREVIBLOC (53%) than with propranolol (17%). The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was rapidly reversible with decreased infusion rate or after discontinuation of therapy with BREVIBLOC.  For both BREVIBLOC and propranolol, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was reported less frequently in patients receiving concomitant digoxin.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f32783a4-3fad-4fb6-9267-37e2a3b17ae5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04a27ee8-ecf3-49ec-95e8-51c29ab0c7de"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">BREVIBLOC PREMIXED Injection</p>
<dl>
<dt>•</dt>
<dd>NDC 10019-055-61, 2500 mg / 250 mL (10 mg/mL) Ready-to-use INTRAVIA Bags</dd>
</dl>
<p>BREVIBLOC DOUBLE STRENGTH PREMIXED Injection</p>
<dl>
<dt>•</dt>
<dd>NDC 10019-075-87, 2000 mg / 100 mL (20 mg/mL) Ready-to-use INTRAVIA Bags</dd>
</dl>
<p>BREVIBLOC Injection</p>
<dl>
<dt>•</dt>
<dd>NDC 10019-115-01, 100 mg / 10 mL (10 mg/mL) Ready-to-use Vials, Package of 25</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91e02119-d1d3-4737-880e-194cd33e5ae6"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 25˚C (77˚F).  Excursions permitted to 15˚-30˚C (59˚-86˚F) <span class="Italics">[see USP Controlled Room Temperature].</span> Protect from freezing. Avoid excessive heat.</p>
<p>Each bag contains no preservative. Once drug has been withdrawn from ready-to-use bag, the bag should be used within 24 hours, with any unused portion discarded.</p>
<p>Visually inspect the container.  If the administration port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p>Do not use plastic containers in series connections.  Such use could result in an <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.</p>
<p>Do not remove unit from overwrap until ready to use.  Do not use if overwrap has been previously opened or damaged.  The overwrap is a moisture barrier.  The inner bag maintains <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the solution.  Tear overwrap at notch and remove premixed bag.  Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  This is normal and does not affect the solution quality or safety.  The opacity will diminish gradually.</p>
<p>Check for minute leaks by squeezing the inner bag firmly.  If leaks are found, discard solution, as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.  Do not use unless the solution is clear (colorless to light yellow) and the seal is intact.</p>
<p>Preparation for intravenous administration:</p>
<dl>
<dt>•</dt>
<dd>Use aseptic technique.</dd>
<dt>•</dt>
<dd>Suspend premixed bag from eyelet support.</dd>
<dt>•</dt>
<dd>Remove plastic protector from delivery port at bottom of bag.</dd>
<dt>•</dt>
<dd>Attach administration set.</dd>
<dt>•</dt>
<dd>Refer to complete directions accompanying set.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_fc89c5f6-d9be-4766-8c24-b9c544650579"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians should inform patients of the risks associated with BREVIBLOC injection:</p>
<dl>
<dt>•</dt>
<dd>The most common adverse reactions are symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) and asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37d27c98-3aaa-4251-af2c-5b38d000b937"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Baxter Logo</span></span></p>
<p>Manufactured for</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Deerfield, IL 60015 USA</p>
<p>Baxter, Brevibloc, Brevibloc Premixed and Intravia are trademarks of Baxter International Inc.</p>
<p>07-19-73-095</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_30c3aca9-336e-4610-9e17-cf8fd02114b6"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id-1431346150"></a><img alt="Brevibloc Representative Container Label NDC 10019-075-87" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-03.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p class="First">Container Label </p>
<p>LOT<br>EXP</p>
<p><span class="Bold">NDC 10019-075-87</span></p>
<p><span class="Bold">Brevibloc</span><br><span class="Bold">DOUBLE STRENGTH</span><br><span class="Bold">Premixed Injection</span><br>Esmolol Hydrochloride in Sodium Chloride<br>2,000 mg/100 mL (20 mg/mL)</p>
<p><span class="Bold">100 mL  Iso-Osmotic • No Preservative Added</span><br><span class="Bold">Single Intravenous Use Only</span></p>
<p>EACH mL CONTAINS 20 mg ESMOLOL HYDROCHLORIDE<br>USP 4.1 mg SODIUM CHLORIDE USP IN WATER <br>FOR INJECTION USP BUFFERED WITH 2.8 mg SODIUM<br>ACETATE TRIHYDRATE USP AND 0.546 mg GLACIAL<br>ACETIC ACID USP pH ADJUSTED WITH SODIUM<br>HYDROXIDE AND/OR HYDROCHLORIC ACID pH 5.0<br>(4.5-5.5) STERILE NONPYROGENIC</p>
<p><span class="Bold">USUAL DOSAGE </span>SEE PACKAGE INSERT</p>
<p><span class="Bold">CAUTIONS </span>CHECK FOR LEAKS BY SQUEEZING<br>CONTAINER FIRMLY IF LEAKS ARE FOUND DISCARD AS <br><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> MAY BE IMPAIRED USE ONLY IF SOLUTION IS <br>CLEAR COLORLESS TO LIGHT YELLOW</p>
<p>DISCARD UNUSED PORTION</p>
<p><span class="Bold">DO NOT INTRODUCE ADDITIVES</span></p>
<p>MUST NOT BE USED IN SERIES CONNECTIONS</p>
<p><span class="Bold">STORE AT 25°C (77°F) EXCURSIONS PERMITTED TO</span><br><span class="Bold">15°-30°C (59°-86°F) [SEE USP CONTROLLED ROOM</span><br><span class="Bold">TEMPERATURE] PROTECT FROM FREEZING</span><br><span class="Bold">AVOID EXCESSIVE HEAT    Rx only</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>DEERFIELD, IL 60015 USA<br>MADE IN USA</p>
<p>460-324-01   <span class="Bold">2J1413</span></p>
<div class="Figure">
<a name="id1323"></a><img alt="Brevibloc Double Strength Representative Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-04.jpg">
</div>
<div class="Figure">
<a name="id1325"></a><img alt="Brevibloc Double Stength Representative Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-05.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>10 x 100 mL Single Use<br>IntraVia containers</p>
<p><span class="Bold">NDC 10019-075-87</span></p>
<p><span class="Bold">Brevibloc DOUBLE STRENGTH</span><br><span class="Bold">Premixed Injection</span></p>
<p><span class="Bold">Esmolol Hydrochloride in Sodium Chloride 2,000 mg/100 mL (20 mg/mL)</span></p>
<p><span class="Bold">Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F).</span> [See <span class="Bold">USP</span><br>Controlled Room Temperature.] <span class="Bold">PROTECT FROM FREEZING. Avoid excessive heat.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in USA</p>
<p>475-345-00    07-06-35-706</p>
<p><span class="Bold">Code 2J1413</span></p>
<p>LOT<br>EXP</p>
<p>For Product Inquiry<br>1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>Baxter, Brevibloc Premixed and IntraVia are <br>trademarks of Baxter International Inc.</p>
<p>BARCODE PLACEMENT ONLY<br>(01)50310019075872(30)0010</p>
<p>10 x 100 mL Single Use<br>IntraVia containers</p>
<p><span class="Bold">NDC 10019-075-87</span></p>
<p><span class="Bold">Brevibloc DOUBLE STRENGTH</span><br><span class="Bold">Premixed Injection</span></p>
<p><span class="Bold">Esmolol Hydrochloride in Sodium Chloride 2,000 mg/100 mL (20 mg/mL)</span></p>
<p><span class="Bold">Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F).</span> [See <span class="Bold">USP</span><br>Controlled Room Temperature.] <span class="Bold">PROTECT FROM FREEZING. Avoid excessive heat.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in USA</p>
<p>475-345-00    07-06-35-706</p>
<p><span class="Bold">Code 2J1413</span></p>
<p>LOT<br>EXP</p>
<p>For Product Inquiry<br>1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>Baxter, Brevibloc Premixed and IntraVia are <br>trademarks of Baxter International Inc.</p>
<p>BARCODE PLACEMENT ONLY *<br>(17)YYMM00(10)XXXXXXX</p>
<p>BARCODE PLACEMENT ONLY<br>(01)50310019075872(30)0010</p>
<p>07-06-35-706</p>
<div class="Figure">
<a name="id110568845"></a><img alt="Brevibloc Representative Container Label NDC 10019-055-61" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-06.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p>Container Label </p>
<p>LOT  EXP</p>
<p><span class="Bold">NDC 10019-055-61</span></p>
<p><span class="Bold">Brevibloc Premixed</span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">Esmolol Hydrochloride </span><br><span class="Bold">in Sodium Chloride</span><br><span class="Bold">2,500 mg/250 mL (10 mg/mL)</span></p>
<p><span class="Bold">250 mL Iso-Osmotic</span><br><span class="Bold">No Preservative Added</span><br><span class="Bold">Single Intravenous Use Only</span></p>
<p>EACH mL CONTAINS 10 mg ESMOLOL<br>HYDROCHLORIDE USP 5.9 mg SODIUM <br>CHLORIDE USP IN WATER FOR INJECTION <br>USP BUFFERED WITH 2.8 mg SODIUM <br>ACETATE TRIHYDRATE USP AND 0.546 mg GLACIAL ACETIC ACID USP <br>pH ADJUSTED WITH SODIUM HYDROXIDE AND/OR HYDROCHLORIC ACID <br>pH 5.0 (4.5-5.5) STERILE NONPYROGENIC</p>
<p><span class="Bold">USUAL DOSAGE </span>SEE PACKAGE INSERT</p>
<p><span class="Bold">CAUTIONS </span>CHECK FOR LEAKS BY SQUEEZING CONTAINER FIRMLY <br>IF LEAKS ARE FOUND DISCARD AS <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> MAY BE IMPAIRED USE<br>ONLY IF SOLUTION IS CLEAR COLORLESS TO LIGHT YELLOW DISCARD <br>UNUSED PORTION</p>
<p><span class="Bold">DO NOT INTRODUCE ADDITIVES</span></p>
<p>MUST NOT BE USED IN SERIES CONNECTIONS</p>
<p><span class="Bold">STORE AT 25°C (77°F) EXCURSIONS PERMITTED TO 15°-30°C</span><br><span class="Bold">(59°-86°F) [SEE USP CONTROLLED ROOM TEMPERATURE]</span><br><span class="Bold">PROTECT FROM FREEZING AVOID EXCESSIVE HEAT  Rx only</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>BAXTER HEALTHCARE CORPORATION<br>DEERFIELD, IL 60015 USA<br>MADE IN USA</p>
<p>INTRAVIA CONTAINER<br>460-327-02  <span class="Bold">2J1415</span></p>
<p>FOR PRODUCT INQUIRY<br>1 800 ANA DRUG<br>(1-800-262-3784)</p>
<div class="Figure">
<a name="id1478"></a><img alt="Brevibloc Representative Carton Label  NDC 10019-055-61" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-07.jpg">
</div>
<div class="Figure">
<a name="id1480"></a><img alt="Brevibloc Representative Carton Label NDC 10019-055-61" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-08.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>10 x 250 mL Single Use<br>IntraVia containers</p>
<p><span class="Bold">NDC 10019-055-61</span></p>
<p><span class="Bold">Brevibloc Premixed Injection</span></p>
<p><span class="Bold">Esmolol Hydrochloride in Sodium Chloride</span><br><span class="Bold">2,500 mg/250 mL (10 mg/mL)</span></p>
<p><span class="Bold">Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F).</span> [See <span class="Bold">USP</span><br>Controlled Room Temperature.] <span class="Bold">PROTECT FROM FREEZING. Avoid excessive heat.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in USA</p>
<p>475-344-00    07-6-35-707</p>
<p><span class="Bold">Code 2J1415</span></p>
<p>LOT<br>EXP</p>
<p>For Product Inquiry<br>1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>Baxter, Brevibloc Premixed and IntraVia are trademarks of Baxter International Inc.</p>
<p>BARCODE PLACEMENT ONLY<br>(01)50310019055614(30)0010</p>
<p>10 x 250 mL Single Use<br>IntraVia containers</p>
<p><span class="Bold">NDC 10019-055-61</span></p>
<p><span class="Bold">Brevibloc Premixed Injection</span></p>
<p><span class="Bold">Esmolol Hydrochloride in Sodium Chloride</span><br><span class="Bold">2,500 mg/250 mL (10 mg/mL)</span></p>
<p><span class="Bold">Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F).</span> [See <span class="Bold">USP</span><br>Controlled Room Temperature.] <span class="Bold">PROTECT FROM FREEZING. Avoid excessive heat.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in USA</p>
<p>475-344-00    07-6-35-707</p>
<p><span class="Bold">Code 2J1415</span></p>
<p>LOT<br>EXP</p>
<p>For Product Inquiry<br>1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>Baxter, Brevibloc Premixed and IntraVia are trademarks of Baxter International Inc.</p>
<p>BARCODE PLACEMENT ONLY<br>(17)YYMM00(10)XXXXXXX</p>
<p>BARCODE PLACEMENT ONLY<br>(01)50310019055614(30)0010</p>
<div class="Figure">
<a name="id1548"></a><img alt="Representative Brevibloc Injection Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-09.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p>Container Label </p>
<p>NDC 10019-115-39</p>
<p><span class="Bold">Brevibloc</span><br><span class="Bold">Injection</span><br><span class="Bold">(Esmolol Hydrochloride)</span></p>
<p><span class="Bold">100 mg/10 mL</span><br><span class="Bold">(10 mg/mL)</span><br>10 mL</p>
<p><span class="Bold">Rx only</span></p>
<p>Ready-to-use Vial</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span><br><span class="Bold">Iso-Osmotic</span><br><span class="Bold">Contains no</span><br><span class="Bold">preservatives-</span><br><span class="Bold">discard unused portion.</span></p>
<p>For Product Inquiry<br>1 800 ANA DRUG (1-800-262-3784)<br>Mfd. for <span class="Bold">Baxter Healthcare Corp.</span><br>Deerfield, IL 60015 USA</p>
<p>462-405-01</p>
<p>LOT:</p>
<p>EXP.: </p>
<div class="Figure">
<a name="id1931236409"></a><img alt="Brevibloc Representative Carton Label NDC 10019-115-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-10.jpg">
</div>
<div class="Figure">
<a name="id536240594"></a><img alt="Brevibloc Representative Carton Label NDC 10019-115-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-11.jpg">
</div>
<div class="Figure">
<a name="id-635026782"></a><img alt="Brevibloc Representative Carton Label NDC 10019-115-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-12.jpg">
</div>
<div class="Figure">
<a name="id73788366"></a><img alt="Brevibloc Representative Carton Label NDC 10019-115-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62&amp;name=image-13.jpg">
</div>
<p>NDC 10019-115-01</p>
<p><span class="Bold">Brevibloc Injection</span><br><span class="Bold">(Esmolol Hydrochloride)</span></p>
<p><span class="Bold">100 mg/10 mL (10 mg/mL)</span><br>25 x 10 mL  Rx only</p>
<p>Ready-to-use Vials</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>NDC 10019-115-01</p>
<p><span class="Bold">Brevibloc Injection (Esmolol Hydrochloride)</span></p>
<p><span class="Bold">100 mg/10 mL (10 mg/mL)</span><br>25 x 10 mL Ready-to-use Vials</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Single Dose Vials</p>
<p><span class="Bold">Iso-Osmotic</span><br><span class="Bold">Contains no preservatives -</span><br><span class="Bold">discard unused portion.</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>NDC 10019-115-01</p>
<p><span class="Bold">Brevibloc Injection (Esmolol Hydrochloride)</span></p>
<p><span class="Bold">100 mg/10 mL (10 mg/mL)</span><br>25 x 10 mL Ready-to-use Vials</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Single Dose Vials</p>
<p><span class="Bold">Iso-Osmotic</span><br><span class="Bold">Contains no preservatives -</span><br><span class="Bold">discard unused portion.</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>NDC 10019-115-01</p>
<p><span class="Bold">Brevibloc Injection (Esmolol Hydrochloride)</span></p>
<p><span class="Bold">100 mg/10 mL (10 mg/mL)</span><br>25 x 10 mL Ready-to-use Vials</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Single Dose Vials</p>
<p><span class="Bold">Iso-Osmotic</span><br><span class="Bold">Contains no preservatives -</span><br><span class="Bold">discard unused portion.</span></p>
<p><span class="Bold"><span class="Italics">Baxter</span></span><br>Manufactured for<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>40602</p>
<p>Each mL contains: 10 mg Esmolol Hydrochloride,<br>USP and 5.9 mg Sodium Chloride, USP in Water <br>for Injection, USP. Buffered with Sodium Acetate<br>Trihydrate, USP and Glacial Acetic Acid, USP.<br>Sodium Hydroxide and/or Hydrochloric Acid added<br>to adjust pH to 5.0 (range 4.5-5.5).</p>
<p><span class="Bold">Store at 25°C (77°F). Excursions permitted to</span><br><span class="Bold">15°-30°C (59°-86°F). [See USP Controlled Room</span><br><span class="Bold">Temperature.] </span>Avoid contact with alkalies. Do not<br>use if discolored or if a precipitate is present.</p>
<p>See package insert for complete information on<br>dosage and administration.</p>
<p>For Product Inquiry 1 800 ANA DRUG<br>(1-800-262-3784)</p>
<p>462-406-02    07-03-73-098</p>
<p>N<br>3   10019   11501  6</p>
<p>LOT:<br>EXP:</p>
<p>40601</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BREVIBLOC 		
					</strong><br><span class="contentTableReg">esmolol hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESMOLOL HYDROCHLORIDE</strong> (ESMOLOL) </td>
<td class="formItem">ESMOLOL HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">2.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">5.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">0.546 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-115-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem">12/31/1986</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-115-39</td>
<td class="formItem">10 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019386</td>
<td class="formItem">12/31/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BREVIBLOC 		
					</strong><br><span class="contentTableReg">esmolol hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-075</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESMOLOL HYDROCHLORIDE</strong> (ESMOLOL) </td>
<td class="formItem">ESMOLOL HYDROCHLORIDE</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">4.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">2.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">0.546 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-075-87</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">12/31/1986</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019386</td>
<td class="formItem">12/31/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BREVIBLOC 		
					</strong><br><span class="contentTableReg">esmolol hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10019-055</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESMOLOL HYDROCHLORIDE</strong> (ESMOLOL) </td>
<td class="formItem">ESMOLOL HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">5.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">2.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">0.546 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10019-055-61</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">250 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019386</td>
<td class="formItem">12/31/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">194684502</td>
<td class="formItem">ANALYSIS(10019-075, 10019-055)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">ANALYSIS(10019-075, 10019-055), LABEL(10019-075, 10019-055), MANUFACTURE(10019-075, 10019-055), PACK(10019-075, 10019-055), STERILIZE(10019-075, 10019-055)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">001728059</td>
<td class="formItem">ANALYSIS(10019-075, 10019-055)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">West Ward Pharmaceutical Corporation, Cherry Hill New Jersey</td>
<td class="formItem"></td>
<td class="formItem">946499746</td>
<td class="formItem">ANALYSIS(10019-115), LABEL(10019-115), MANUFACTURE(10019-115), PACK(10019-115), STERILIZE(10019-115)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lancaster Laboratories</td>
<td class="formItem"></td>
<td class="formItem">069777290</td>
<td class="formItem">ANALYSIS(10019-115)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1c8aa9ee-8b8d-4908-b70d-619a857fb1c5</div>
<div>Set id: 595cc3d5-1306-4828-aefa-5595219ffd62</div>
<div>Version: 7</div>
<div>Effective Time: 20140401</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
